1. Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical Trials 
Hugh Taggart, MD, Michael A. Bolognese, MD, Robert Lindsay, MD, PHD, Mark P. Ettinger, MD, Henk Mulder, MD, PHD, Robert G. Josse, MBBS, Anthony Roberts, MBBS, Hartmut Zippel, MD, Silvano Adami, MD, Teresa F. Ernst, PHARMD, Karen P. Stevens, PHARMD 
Mayo Clinic Proceedings 
Volume 77, Issue 3, Pages (March 2002)
DOI: /
Copyright © 2002 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Comparison of percentages of patients with upper gastrointestinal (GI) tract adverse events between patients who were users or nonusers of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or aspirin or proton pump inhibitors (PPIs) and/or H2-receptor antagonists (H2-RAs) in the risedronate and alendronate treatment groups.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2002 Mayo Foundation for Medical Education and Research Terms and Conditions